Neoplasie della testa e del collo e trattamenti combinati
|
|
- Meryl Stewart
- 5 years ago
- Views:
Transcription
1 Neoplasie della testa e del collo e trattamenti combinati 2 nd Young Sicilian Oncologists Day: Linee Guida AIOM, Appropriatezza e Medicina di precisione Messina Ottobre 2017 NERINA DENARO denaro.n@ospedale.cuneo.it
2 EPIDEMIOLOGY 6 malignancy worldwide (6% of all cases /1% 2% of all deaths) Oral cavity 44%; larynx 31%; pharynx 25% European annual incidence of 43/ Italian annual incidence 20/ Survival in HNSCC is predicted primarily by - anatomical site - stage - HPV status - other pathological and clinical factors influencing prognosis to a lesser degree 2
3 2HNC Tobacco-related HNSCC mutation of the p53 gene and downregulation of the p16 protein HPV-associated OPC wt p53 and Rb genes and upregulation of p53 protein levels 3
4 HPV IMMUNOESCAPE 1. Weak T cell response to HPV early Ag in blood (downregulation HLA I/inhibition STAT1) 2. TILs that often lack cytotoxicity (Tregs) 3. TILs that express co-inhibitory molecules such as PD1, TGFβ at their surface and have a downregulation of CD3 complex and OX40 and IL2 response 4. Incresed number of IL 10 producing Treg 5. Loss of IFNƔ 6. E5 interacts with HLA-I heavy chain, resulting in reduced cell surface HLA-I 7. E6 inhibits the STAT-1 pathway. Destruction of p53 8. E7 down-regulates cell expression both of HLA class I, and transporter associated with antigen processing (TAP) [Li W, 2010]. E7 interacts with IRF-1 and disrupts its control [Um SJ 2002]. Inactivation rb 4
5 HPV Distinct subset of HNSCC Primarily oropharynx. HPV16 90% of HPV+ OPCs. The time from first oral HPV infection to the development of cancer is estimated to be more than a decade. Measures of sexual behaviour (number of vaginal and oral partners, history of genital warts) have been associated with HPV+ OPC. 5
6 HNSCC Treatment STAGE I S or RT STAGE II S eventually followed by RT or in selected pts only RT Stage III S RT±CT (resectable) Stage IVa-b CTRT(unresectable) Stage IV c CT Postop RT (pathological minor risk factors): Poor differentiation grade (G3) /Perineural and/or vascular invasion/ Number of pathologically positive lymph nodes ( 2)/ pt3, pt4, close margins In selected non-radical excision, re-excision can be considered. Concurrent CTRT ( major risk factors): R1 resection (resection with microscopic residual disease)/ Lymph node extranodular extension (ENE) Multidisciplinary team is MANDATORY for adeguate management Lo Nigro C
7 HNSCC Treatment 5-y OS St I-II = 70% 85%. 5-y OS St III-IV = ~ 50%. 5-y OS St I-II = 80% 95%. 5-y OS St III-IV = ~ 40%. 5-y OS St I-II = 70% 80%. 5-y OS St III-IV = ~ 30%. 5-y OS St I-II = 80% 95%. 5-y OS St III-IV = ~ 40%. 7
8 ADEGUATE SUPPORTIVE CARE Accurate patient selection and an individualised supportive care approach are mandatory BEFORE treatment initiation, DURING and AFTER tretment because allow program completion. CTRT is associated with severe acute toxicities, which can result in a mortality rate ranging from 2% to 9.3%. > acute toxicity > late adverse events <patients QoL and possibly cause late death Lo Nigro C 2017
9 ADEGUATE SUPPORTIVE CARE Adequate oral care Dysphagia assessment before and during treatment It is recommended to minimise the dose to the main DARS A 3-drug regimen with a 5-HT3 receptor antagonist,dexamethasone and an NK1 receptor antagonist for the prevention of cisplatin-induced nausea and vomiting. ESAs are NOT recommended in patients treated with curative intent with radiotherapy (DETRIMENTAL) Dietary counselling and/or supplements. Febrile neutropaenic HNC patients should be hospitalised. In case of Grade 3 skin and haematologic toxicity, do not stop radiotherapy 9
10 FUTURE DIRECTIONS
11 IMMUNOTHERAPIES IN HNC 1. Monoclonal Antibodies 2. Checkpoint Inhibitors 3. Vaccination 4. Adoptive therapy/car/tils 11
12 OS (%) CETUXIMAB BioRT R/M HNSCC CT* alone (n=220) -PF Cetuximab(n=222) 7.4 months HR=0.80, p= months Months 5 y OS 46% vs 36% 81% DCR in the cet arm 27% reduction in death risk (HR=0.73) Rash intensity correlates with > OS >OS in all primary sites Bonner et al Lancet Oncol 2010 Vermorken JB, et al. N Engl J Med 2008;359:
13 CETUXIMAB Cetuximab NK cell activation 1 Tumor cell EGFR Lysis 1 Cetuximab NK cell FC Receptor Dendritic cell activation and T cell recruitment 2 Tumor cell FC region of antibody Cetuximab also attenuates the decrease in T and NKT cells seen with platinum + 5-FU 3 1. Trivedi S, et al. Ann Oncol 2015;26:40 47; 2. Belluci R, et al. OncoImmunol 2015;4:6,e ; 3. Lo Nigro C, et al. Cancer Res 2015;75:
14 Biomarker for immune activity of Cetuximab? Lattanzio L
15 Immunocheckpoint inhibitors (ICI) CheckMate KEYNOTE-055 2,3 N=361 KEYNOTE N=132 *ITT population (Note: 13 patients actually received cetuximab); ASCO 2016 data cover analysis of the first 50 patients 1. Ferris RL, et al. ASCO 2016 (Abstract No. 6009); 2. Bauml J, et al. ASCO 2016 (Abstract No. 6011); 3. (Accessed NOv, 2016); 4. Chow LQ, et al. ASCO 2016 (Abstract No. 6010) 15
16 OS (%) Overall Survival, Minimum Follow-up: 11.4 Months Nivo IC Months No. of patients at risk CheckMate 141: Nivolumab in R/M SCCHN After Platinum Therapy 12-mo OS = 34.0% 19.7% 18-mo OS = 21.5% % Median OS, mo (95% CI) Nivolumab (n = 240) 7.7 (5.7, 8.8) 0.71 Investigator s choice (n = 121) 5.1 (4.0, 6.2) HR (95% CI) P value (0.55, 0.90) Nivolumab Investigator s choice Adapted by Haddad CM-141 IC = investigator s choice Gillison ML, et al. J Clin Oncol 2017;35(suppl): abstract
17 CHECKMATE 141 Among patients achieving CR/PR, nivo improved OS compared with IC Median OS was not reached vs 13.6 months (HR = 0.08; 95% CI: 0.01, 0.47) 18-month survival rates were 86.1% vs 38.1% Patients with SD are not considered responders per RECIST 1.1, but treatment with nivolumab resulted in survival benefits compared with IC Median OS was 10.4 vs 7.1 months (HR = 0.53; 95% CI: 0.33, 0.85) 18-month survival rates were 32.6% vs 11.7% Nivolumab s safety profile was favorable vs IC, including for patients with CR/PR who were on therapy longer (median duration, >12 months vs <5 months) 17
18 CHECKMATE 141 Ferris RL AACR
19 KEYNOTE pts Median PFS 2 m 6 m PFS: HPV+ = 37% HPV - = 20% Median OS 8 m 6 m OS: HPV+ = 70 % HPV - = 56 % 19
20 KEYNOTE pts 82% PDL1 pos 22% HPV pos 20
21 Keynote
22 Keynote
23 TOXICITY 23
24 Checkmate pts pre surgery response in 11/23 (48% ) RECIST Criteria Reductions were seen in both HPV+ and HPV tumors 3 pts had tumor reduction 40% The largest reduction was 75% in 1 pt HPV+ Grade 3 4 TRAEs occurred in 2 (16.7%) pts HPV+ and 2 (11.8%) pts HPV Serious TRAEs occurred in 1 (8.3%) patient with an HPV+ tumor and 3 (17.6%) patients with HPV tumors 24
25 Tumor Reduction in PTS Treated beyond pd Courtesy R. Haddad 25
26 2 line Comparison 26
27 2 line Comparison 27
28 ACTIVITY ORR Checkmate 141 Keynote 040 Nivo SOC Pembro SOC CR PR No Resp % ( ) 5.8% ( ) 14.6% 10.1% LUX Head & Neck 1 ORR AFATINIB METHOTREXATE CR 0 0 PR 33 (10%) 9 (6%) No Resp
29 The future: combination Economopulou P PD1/PDL1+CTLA4 PD1+CD137 (urelumab) PD1+anti KIR (lirilumab PD1+IDO Oncolytic virus/gm-csf+pd1 (TVec) PD1+RT±CT PD1+EGFR Blanck CU 2016 Science 29
30 The future: combination RT IT ICI CT TT Economopoulou P
31 The future: combination Economopoulou P
32 Immunotherapy for HNC : conclusions Few responders but long survivors Unclear treatment duration and position of IC in the therapeutic algoritm 1. Need for selection Biomarkers gene signatures TAIC, NLR 2. Need of «useful»trials 32
33 BIOMARKERS 33
34 Conclusions In LAHNSCC outcome depends on both clinical /pathological prognostic factor and on multidisciplinary team expertise /protocol adherence Acute and late treatment sequalae impact on quality of life and overall survival ICI therapy, specifically PD1 pathway blockade, improves survival in R/M HNC independently from the number of prior treatment lines Achievement of an OR during ICI therapy predicts a good outcome (considering the # line of treatment) The ideal biomarker to select ICI responders is unknown What immuno-oncology (IO) combinations make sense for HNC? Which position in our treatment flow chart? What are the optimal dose,fractionation and field size in IO-RT for LAHNC? 34
35 GRAZIE per l attenzione Neoplasie della testa e del collo e trattamenti combinati 35
Role of immunotherapy in virus related head and neck cancer Nerina Denaro
Role of immunotherapy in virus related head and neck cancer Nerina Denaro Oncologia ASO S. Croce e Carle Cuneo Virus-related HNC HNSCC (oropharynx) HPV Nasopharyngeal Cancer (NPC) EBV EBV 1 st human virus
More informationPractice teaching course on head and neck cancer management
28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicolas Magné France
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationCarla van Herpen Medical Oncologist Immunotherapyin Head & NeckCancer
Carla van Herpen Medical Oncologist 01-10-2016 Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial,
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationState of the Art: Management of Squamous Cell Carcinoma of the Head and Neck. Raul Giglio
State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck Raul Giglio Disclosures Nothing to disclose SCCHN Outline 1. General considerations: MTD 2. Epidemiology 3. Locoregional disease
More informationNew Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
More informationConcurrent Chemo- and Radiotherapy for Ororpharynx Cancer
Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-
More informationSAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital
SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationEmerging immune biomarkers. Athanasios Kotsakis MD, PhD Ast. Professor of Medical Oncology School of Medicine, University of Crete
Emerging immune biomarkers Athanasios Kotsakis MD, PhD Ast. Professor of Medical Oncology School of Medicine, University of Crete Disclosure: none Cancer Immunotherapy Immunotherapy, mainly anti PD 1/PD
More informationHead and Neck Cancer:
Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationHead and Neck Cancer Update Sandro V Porceddu
Head and Neck Cancer Update Sandro V Porceddu Director, Radiation Oncology Research Princess Alexandra Hospital, Brisbane Associate Professor, University of Queensland President, Trans Tasman Radiation
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationand neck cancers, 2018
Emerging systemic treatments for head and neck cancers, 2018 A. DIMITRIOS COLEVAS, MD PROFESSOR OF MEDICINE (ONCOLOGY) AND, BY COURTESY, OF OTOLARYNGOLOGY - HEAD AND NECK SURGERY AT THE STANFORD UNIVERSITY
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationLaryngeal and hypopharyngeal cancers
Laryngeal and hypopharyngeal cancers Induction Chemotherapy in combined modality approaches Atenas 16.09.2017 Ana Ferreira Castro, MD Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationINMUNOTERAPIA: NUEVO PARADIGMA EN LOS TUMORES DE CABEZA Y CUELLO. Dra. Lara Iglesias H.U.12 Octubre
INMUNOTERAPIA: NUEVO PARADIGMA EN LOS TUMORES DE CABEZA Y CUELLO Dra. Lara Iglesias H.U.12 Octubre INTRODUCCIÓN INFORME SEOM DE EVALUACIÓN DE FÁRMACOS: NIVOLUMAB EN CÁNCER EPIDERMOIDE DE CABEZA Y CUELLO
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationPresent and Future of Head and Neck Cancer Therapy (Focus at systemic therapy)
Present and Future of Head and Neck Cancer Therapy (Focus at systemic therapy) Jan B; Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 1st Hellenic Conference
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationCurrent patient journey in SCCHN
Contents Current patient journey in SCCHN 1 st line options for R/M SCCHN 2 nd line treatmens options for R/M SCCHC The evolving continuum of care in R/M SCCHH Current patient journey in SCCHN 1. Mabanta
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationNew Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL
New Agents for Head and Neck Cancer Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL Disclosure Dr. Cohen has the following relevant financial relationships with commercial
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationSequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital
Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationNuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA. Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana
Nuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana Until now: Some success Kantoff et al, N Engl J Med 2010 Kantoff et
More informationRadiotherapy of head and neck cancer
ФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России Radiotherapy of head and neck cancer S.N. Novikov ФГБУ «НИИ онкологии им. Н.Н. Петрова» Минздрава России Postoperative radiotherapy Radiotherapy
More informationRecent Advances & Ongoing Challenges in Head & Neck Cancers
Recent Advances & Ongoing Challenges in Head & Neck Cancers Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School Boston, MA Disclosures
More informationImmunotherapy and Targeted Therapies: The new face of cancer treatment
Immunotherapy and Targeted Therapies: The new face of cancer treatment Abdulazeez Salawu MBBS, MSc, PhD, MRCP Academic Clinical Lecturer Weston Park Hospital, Sheffield Novel Systemic Anti-cancer Therapies
More informationNew Systemic Therapies in Advanced Melanoma
New Systemic Therapies in Advanced Melanoma Sanjay Rao, MD FRCPC Medical Oncologist (BCCA-CSI) Clinical Assistant Professor, UBC Faculty of Medicine SON Fall Update October 22, 2016 Disclosures Equity
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More information17th ESO-ESMO Masterclass Clinical Oncology
Chemoradiotherapy and Systemic Therapy in Squamous Cell Carcinoma of the Head and Neck (SCCHN) Jan B. Vermorken, MD, PhD Department of Medical Oncology Antwerp University Hospital Edegem, Belgium 17 th
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationUpdates and best practices in the management of gastric cancer
Updates and best practices in the management of gastric cancer Olatunji B. Alese, MD Gastrointestinal Oncology, Winship Cancer Institute of Emory University July 28, 2017 1 Incidence 3rd leading cause
More informationTake home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone
II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationHead and NeckCancer: multi-modal therapeuticintegration
Head and NeckCancer: multi-modal therapeuticintegration P. Ponticelli, L. Lastrucci, R. De Majo, A. Rampini U.O.C. Radioterapia Ospedale S. Donato ASL 8 -AREZZO Summary Biological considerations Clinical
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationFattori predittivi di efficacia ed interpretazione della risposta all immunoterapia. Dott. Matteo Brighenti Oncologia Cremona
Fattori predittivi di efficacia ed interpretazione della risposta all immunoterapia Dott. Matteo Brighenti Oncologia Cremona AREA DI RICERCA CLINICA EPIDEMIOLOGICA ONCOLOGIA CREMONA mos in 4 phase III
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationOral Cavity Cancer Combined modality therapy
Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More information